DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Wu YL, Zhou C, Hu CP et al.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Lancet Oncol 2014;
15: 213-222
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.